^
Association details:
Biomarker:No biomarker
Cancer:Clear Cell Renal Cell Carcinoma
Drug:pazopanib (Multi-tyrosine kinase inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
09/28/2021
Excerpt:
First-line treatment for advanced ccRCC...Sunitinib [I, A], pazopanib [I, A] and tivozanib [II, B; ESMO-MCBS v1.1 score: 1] are alternatives to PD-1 inhibitor-based first-line combinations when immune therapy is contraindicated or not available.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
The NCCN Kidney Cancer Panel has listed pazopanib as a category 1 preferred option for first-line treatment of patients with favourable risk features with relapsed or medically unresectable clear cell stage IV RCC.